Vepoloxamer
drugOn this page
Also known as Kolliphor p 188Kolliphor p188Lutrol f 68Lutrol f68MST-188Pluracare f 68Pluronic f-68Pluronic f68Pluronic f68lfPoloxalkolPoloxamer - 188Poloxamer 188Poloxamer 188lfPoloxamer-188Polykol
Summary
Vepoloxamer (CHEMBL3137355) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including sickle cell disease and heart failure.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 4 conditions
- Clinical trials: 6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3137355 |
| Name | Vepoloxamer |
| Type | Small molecule |
| Max phase | 3 |
Also known as: Kolliphor p 188, Kolliphor p188, Lutrol f 68, Lutrol f68, MST-188, Pluracare f 68, Pluronic f-68, Pluronic f68, Pluronic f68lf, Poloxalkol, Poloxamer - 188, Poloxamer 188
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| sickle cell disease | 3 | MONDO:0011382 | MONDO:0011382 |
| heart failure | 2 | MONDO:0005252 | EFO:0003144 |
| ischemic disease | 2 | MONDO:0005053 | EFO:0000556 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE2 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00004408 | PHASE3 | COMPLETED | Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease |
| NCT01737814 | PHASE3 | COMPLETED | Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) |
| NCT02449616 | PHASE3 | COMPLETED | Evaluation of Repeat Administration of Purified Poloxamer 188 |
| NCT02093468 | PHASE2 | TERMINATED | Evaluation of MST-188 in Acute Lower Limb Ischemia |
| NCT02596477 | PHASE2 | TERMINATED | Evaluation of Vepoloxamer in Chronic Heart Failure |
| NCT02646358 | PHASE1 | COMPLETED | Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: sickle cell disease